Stockreport

Eli Lilly keeps up ophthalmic gene therapy push with $475m MeiraGTx deal [Yahoo! Finance]

MeiraGTx Holdings plc - Ordinary Shares  (MGTX) 
PDF Eli Lilly will pay UK-based MeiraGTx $75m upfront for global exclusive rights to AAV-AIPL1, a gene therapy in development for a rare form of inherited blindness, along [Read more]